News & Updates
Filter by Specialty:
Resmetirom proves efficacy in NASH patients with or without MetALD
20 Jun 2024
byStephen Padilla
Patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis treated with resmetirom achieve NASH resolution with no fibrosis worsening (NR) or ≥1-stage fibrosis improvement with no worsening of the NAS score (FI), according to the results of the ongoing MAESTRO-NASH study.
Resmetirom proves efficacy in NASH patients with or without MetALD
20 Jun 2024
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
byAudrey Abella
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
Physical activity substantially cuts cirrhosis risk in MASLD patients
19 Jun 2024
byAudrey Abella
A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
